XON - Intrexon Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.4700
+0.3200 (+7.71%)
As of 2:02PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.1500
Open4.1600
Bid4.4600 x 4000
Ask4.4700 x 900
Day's Range4.1200 - 4.4750
52 Week Range3.9500 - 19.9400
Volume3,284,719
Avg. Volume2,549,738
Market Cap718.418M
Beta (3Y Monthly)2.18
PE Ratio (TTM)N/A
EPS (TTM)-3.9320
Earnings DateMay 8, 2019 - May 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.67
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    AquaBounty Technologies, Inc. Announces Exercise of Option to Purchase Additional Shares

    MAYNARD, Mass., April 17, 2019 -- AquaBounty Technologies, Inc. (Nasdaq: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the.

  • Fibrocell Out-licenses Skin Disease Gene Therapy, Stock Rises
    Zacks7 days ago

    Fibrocell Out-licenses Skin Disease Gene Therapy, Stock Rises

    Fibrocell (FCSC) collaborates with Castle Creek to develop/commercialize its gene therapy candidate, FCX-007, for the rare skin disease of recessive dystrophic epidermolysis bullosa. Stock jumps.

  • PR Newswire7 days ago

    Oxitec Signs New Multi-year Development Agreement to Apply 2nd Generation Technology to Control Soybean Looper

    Oxitec to develop a safe, self-limiting insect capable of reducing pest populations and reversing insect resistance to biotech traits and chemistries OXFORD, England , April 16, 2019 /PRNewswire/ -- Oxitec ...

  • GlobeNewswire8 days ago

    Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy

    Fibrocell Science, Inc. (FCSC), a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced the completion of a collaboration agreement with Castle Creek Pharmaceuticals to develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare, life-threatening genetic disorder diagnosed at infancy with no cure or treatment approved by the U.S. Food and Drug Administration (FDA). “We are proud to partner with Castle Creek Pharmaceuticals, a company recognized for its innovation in drug development for rare skin diseases and its commitment to the epidermolysis bullosa community.

  • PR Newswire13 days ago

    Intrexon to Highlight Microbial Cannabinoid Production Platform at the Paradigm Capital Biosynthesis Conference

    GERMANTOWN, Md. , April 10, 2019 /PRNewswire/ --   Intrexon Corporation  (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...

  • GlobeNewswire14 days ago

    AquaBounty Technologies, Inc. Announces Closing of Public Offering of Common Stock

    MAYNARD, Mass., April 09, 2019 -- AquaBounty Technologies, Inc. (Nasdaq: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the.

  • Markit14 days ago

    See what the IHS Markit Score report has to say about Intrexon Corp.

    Intrexon Corp NASDAQ/NGS:XONView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is high for XON with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting XON. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold XON had net inflows of $2.76 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Oxitec Advances Self-Limiting Fall Armyworm Control Solution to Next Phase of Development
    PR Newswire14 days ago

    Oxitec Advances Self-Limiting Fall Armyworm Control Solution to Next Phase of Development

    OXFORD, England, April 9, 2019 /PRNewswire/ -- Oxitec Ltd., a wholly-owned subsidiary of Intrexon (XON), today announced it has entered into a second agreement with a collaborator to advance the next phase of development of its self-limiting fall armyworm control solution. This announcement comes after the successful conclusion of an initial three-year research and development collaboration that funded the early development of the self-limiting fall armyworm strain.

  • Why Intrexon Stock Dropped 34% in March
    Motley Fool15 days ago

    Why Intrexon Stock Dropped 34% in March

    Investors weren't happy to learn about its worsening cash position.

  • GlobeNewswire19 days ago

    AquaBounty Technologies, Inc. Announces Pricing of $5.75 Million Public Offering of Common Stock

    MAYNARD, Mass., April 04, 2019 -- AquaBounty Technologies, Inc. (Nasdaq: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the.

  • GlobeNewswire19 days ago

    AquaBounty Technologies, Inc. Announces Proposed Public Offering of Common Stock

    AquaBounty Technologies, Inc. (AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (XON), today announced that it has commenced a proposed underwritten public offering of common stock of the Company. In addition, the Company expects to grant the underwriter of the offering a 45-day option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.

  • PR Newswire20 days ago

    Intrexon Intensifies Focus on Healthcare, Forms Two Units and Streamlines Management

    - Move prompted by rapid progress at Intrexon's Precigen subsidiary - - Two therapeutic candidates from Precigen's game-changing UltraCAR-T™ therapeutic platform commencing clinical studies - GERMANTOWN, ...

  • GlobeNewswire21 days ago

    AquaBounty Technologies, Inc. Environment and Climate Change Canada Approves Rollo Bay Facility for Commercial Production of AquAdvantage Salmon

    AquaBounty Technologies, Inc. (AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (XON), announces that Environment and Climate Change Canada (ECCC) has approved the Company’s Rollo Bay production facility for the commercial manufacture and grow-out of AquAdvantage Salmon. After an extensive and thorough evaluation, ECCC approved the production of AquAdvantage Salmon at the site based on the physical, biological, and operational measures in place or planned at the Rollo Bay facility.

  • Why Is Intrexon (XON) Down 34% Since Last Earnings Report?
    Zacks24 days ago

    Why Is Intrexon (XON) Down 34% Since Last Earnings Report?

    Intrexon (XON) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Next Green Wave's Nursery Botticelli(TM) Research & Development Program Begins
    Newsfilelast month

    Next Green Wave's Nursery Botticelli(TM) Research & Development Program Begins

    Next Green Wave begins to implement Intrexon Botticelli(TM) next generation (non-GMO) tissue culture platform toward rapid and sustainable cannabis plantlet production Vancouver, British Columbia--(Newsfile Corp. - March 22, 2019) - Next Green Wave Holdings Inc. (CSE: NGW) (OTCQB: NXGWF) ("Next Green Wave", "NGW" or the "Company"), is pleased to announce that is has begun the optimization phase of the strategic licensing agreement with Intrexon Corporation (NASDAQ: XON) ("Intrexon") to utilize Intrexon's Botticelli™ next generation plant ...

  • GlobeNewswirelast month

    AquaBounty Technologies, Inc. Announces Closing of Public Offering of Common Stock

    MAYNARD, Mass., March 21, 2019 -- AquaBounty Technologies, Inc. (Nasdaq: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the.

  • Benzingalast month

    Jim Cramer Shares His Thoughts On Ambarella, Centurylink, Chipotle And More

    On CNBC's "Mad Money Lightning Round" , Jim Cramer said he would sell Centurylink Inc (NYSE: CTL ). Everything in the life sciences sector is a buy, said Cramer. He is a buyer of Fluidigm Corporation ...

  • GlobeNewswire2 months ago

    AquaBounty Technologies, Inc. - FDA Lifts Import Alert on AquAdvantage Salmon

    AquaBounty Technologies, Inc. (AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (XON), announces the U.S. Food and Drug Administration (FDA) lifting of the Import Alert, allowing the Company to start farming AquAdvantage Salmon in Indiana.

  • GlobeNewswire2 months ago

    AquaBounty Technologies, Inc. Results for the year ended December 31, 2018

    MAYNARD, Mass., March 07, 2019 -- AquaBounty Technologies, Inc. (NASDAQ: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of XON earnings conference call or presentation 28-Feb-19 10:30pm GMT

    Q4 2018 Intrexon Corp Earnings Call

  • Here's What Caused Intrexon's 21% Rally Today
    Motley Fool2 months ago

    Here's What Caused Intrexon's 21% Rally Today

    The company got welcome support from a big money manager.